Exenatide vs Semaglutide

Q: Is Exenatide better than Semaglutide?

Semaglutide has a higher evidence score (8.5/10 vs 6/10) and wins in 2 of 3 categories.

Q: Is Exenatide or Semaglutide better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 46).

Q: Can I take Exenatide and Semaglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Exenatide vs Semaglutide: Semaglutide has the stronger overall evidence (8.5 vs 6/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Semaglutide Edges Ahead

Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Exenatide0 wins

Semaglutide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Exe6.0

Exenatide

Too few graded studiesLimited safety

Sgl8.5

Semaglutide

Too few graded studiesLimited safety

Evidence

Evidence Score

6/10

Studies: 113

Meta-analyses: 24

Level: Moderate

Evidence Score

Best8.5/10

Studies: 455

Meta-analyses: 134

Level: Very Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies64
Weight managementToo few graded studies23
Cardiovascular outcomesToo few graded studies18

Verdict

Too few graded studies

Top outcomes

Blood sugar & glycemic controlToo few graded studies197
Weight managementToo few graded studies182
Cardiovascular outcomesToo few graded studies58

Shared outcomes (3)

Outcomes where both Exenatide and Semaglutide have evidence — compare verdict strength side-by-side.

Blood sugar & glycemic controlToo few graded studies64Too few graded studies197
Weight managementToo few graded studies23Too few graded studies182
Cardiovascular outcomesToo few graded studies18Too few graded studies58

Dosage & timing

Recommended Dosage:

Prescription-only, clinician-directed. Subcutaneous. Byetta (twice-daily): 5 µg before two main meals, escalated to 10 µg after ~1 month. Bydureon (once-weekly extended-release): 2 mg subcutaneously once weekly. DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA BOXED WARNING (extended-release exenatide, Bydureon BCise): thyroid C-cell tumors. GLP-1 receptor agonists cause thyroid C-cell (medullary) tumors in rodents; human relevance is undetermined. Under that US label, contraindicated with a personal/family history of medullary thyroid carcinoma (MTC) or MEN2. Immediate-release Byetta does not carry this US boxed warning. The EU marketing authorisations for Byetta and Bydureon were withdrawn on 1 January 2026 at the company’s request for commercial reasons. In Germany or Austria, discuss current availability and authorised alternatives with your prescriber. Do not stop or change your prescribed diabetes treatment on your own.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis) — a meta-analysis of GLP-1 agonists found a significantly increased cholelithiasis risk.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are common, especially early and during dose escalation.
Renal: exenatide is renally cleared — avoid in severe renal impairment (eGFR <30) and dialysis; cases of acute kidney injury have been reported, often with dehydration from GI losses.
Injection-site reactions (nodules/induration) are more common with the once-weekly depot.
Cardiovascular benefit is NOT established: the EXSCEL outcomes trial was neutral on its primary endpoint (HR 0.91; P=0.06) — unlike liraglutide, semaglutide and dulaglutide. Do not assume class-wide CV protection.
May increase hypoglycemia risk when combined with sulfonylureas or insulin (dose adjustment needed).
Largely superseded by newer, more potent GLP-1 agents — discuss alternatives with a clinician.
Avoid COMPOUNDED / grey-market exenatide: risk of dosing errors, impurities, and unapproved product. Use only pharmacy-dispensed product.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly extended-release injection (Bydureon)

Recommended Dosage:

Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.
Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.
Post-marketing reports of ileus (severely slowed gut motility).
May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.
Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.
FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.
Not for cosmetic weight loss without a genuine medical indication.
May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Subcutaneous once-weekly injection (Ozempic / Wegovy)

Safety

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Sulfonylureas and insulin (moderate)
Oral medications (general) (moderate)

and 1 more not shown

Side Effects:

NauseaVomiting / diarrheaInjection-site nodules / induration (once-weekly form)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label for extended-release exenatide, Bydureon BCise, not for immediate-release Byetta)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label for extended-release exenatide, Bydureon BCise, not for immediate-release Byetta)

Limited safetyTie

Drug Interactions:

Other GLP-1 receptor agonists (severe)
Insulin and sulfonylureas (moderate)
Oral medications (general) (moderate)

Side Effects:

NauseaVomiting / diarrhea / constipationGallbladder disease (cholelithiasis / cholecystitis)

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple Endocrine Neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Shared goals

Manage weightSemaglutide

Exenatide46/100

Semaglutide88/100

Manage blood sugarSemaglutide

Exenatide66/100

Semaglutide85/100

What you'll notice

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Modest weight losspositive

Months

❤️ Cardiovascular: neutral primary outcomeneutral

Years

🤢 GI adverse effects (common)trade-off

Especially early / during dose escalation

🩸 Improved glycemic controlpositive

Weeks to months

⚖️ Substantial weight losspositive

Months (titrated over 16-20 weeks)

❤️ Reduced cardiovascular eventspositive

Months to years

🤢 GI adverse effects (very common)trade-off

Especially during dose escalation

Key studies

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL).

N Engl J Med (2017) · Rct · n=14752

Large cardiovascular-outcomes RCT: 14,752 patients with type 2 diabetes (73.1% with prior cardiovascular disease), once-weekly exenatide 2 mg vs placebo added to usual care, median 3.2 years

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes (DURATION-1): a randomised, open-label, non-inferiority study.

Lancet (2008) · Rct · n=295

30-week open-label RCT in 295 patients with type 2 diabetes comparing once-weekly extended-release exenatide 2 mg with 10 µg twice daily

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.

Lancet (2013) · Rct · n=911

26-week head-to-head open-label RCT in 911 patients: once-weekly exenatide 2 mg vs once-daily liraglutide 1.8 mg added to oral therapy

All Exenatide studies

Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).

N Engl J Med (2021) · Rct · n=1961

Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).

N Engl J Med (2023) · Rct · n=17604

Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).

N Engl J Med (2016) · Rct · n=3297

Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks

All Semaglutide studies

Frequently asked questions

Is Exenatide better than Semaglutide?

Semaglutide has a higher evidence score (8.5/10 vs 6/10) and wins in 2 of 3 categories.

Is Exenatide or Semaglutide better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 46).

Can I take Exenatide and Semaglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Exenatide vs Tirzepatide Exenatide vs Liraglutide Exenatide vs Thiamine Semaglutide vs Tirzepatide Liraglutide vs Semaglutide AREDS2 Formula vs Semaglutide

Still deciding between Exenatide and Semaglutide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Exenatide details Semaglutide details

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA BOXED WARNING (extended-release exenatide, Bydureon BCise): thyroid C-cell tumors. GLP-1 receptor agonists cause thyroid C-cell (medullary) tumors in rodents; human relevance is undetermined. Under that US label, contraindicated with a personal/family history of medullary thyroid carcinoma (MTC) or MEN2. Immediate-release Byetta does not carry this US boxed warning. The EU marketing authorisations for Byetta and Bydureon were withdrawn on 1 January 2026 at the company’s request for commercial reasons. In Germany or Austria, discuss current availability and authorised alternatives with your prescriber. Do not stop or change your prescribed diabetes treatment on your own.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis) — a meta-analysis of GLP-1 agonists found a significantly increased cholelithiasis risk.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea) are common, especially early and during dose escalation.

Renal: exenatide is renally cleared — avoid in severe renal impairment (eGFR <30) and dialysis; cases of acute kidney injury have been reported, often with dehydration from GI losses.

Injection-site reactions (nodules/induration) are more common with the once-weekly depot.

Cardiovascular benefit is NOT established: the EXSCEL outcomes trial was neutral on its primary endpoint (HR 0.91; P=0.06) — unlike liraglutide, semaglutide and dulaglutide. Do not assume class-wide CV protection.

May increase hypoglycemia risk when combined with sulfonylureas or insulin (dose adjustment needed).

Largely superseded by newer, more potent GLP-1 agents — discuss alternatives with a clinician.

Avoid COMPOUNDED / grey-market exenatide: risk of dosing errors, impurities, and unapproved product. Use only pharmacy-dispensed product.

Warnings

This is a PRESCRIPTION DRUG, not a dietary supplement — use only under a clinician's care for an approved medical indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: semaglutide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Risk of acute pancreatitis — discontinue and seek care for severe persistent abdominal pain.

Risk of gallbladder disease (gallstones, cholecystitis), particularly with rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are very common, especially during dose escalation.

Post-marketing reports of ileus (severely slowed gut motility).

May worsen pre-existing diabetic retinopathy, attributed to rapid improvement in glucose control — ensure ophthalmologic monitoring in patients with a history of diabetic retinopathy.

Weight loss includes loss of lean muscle mass — pair with resistance training and adequate protein.

FDA has warned about COMPOUNDED / grey-market semaglutide: risk of dosing errors, impurities, and unapproved salt forms. Use only pharmacy-dispensed product.

Not for cosmetic weight loss without a genuine medical indication.

May increase hypoglycemia risk when combined with insulin or sulfonylureas (dose adjustment needed).

Frequently asked questions

Is Exenatide better than Semaglutide?

Semaglutide has a higher evidence score (8.5/10 vs 6/10) and wins in 2 of 3 categories.

Is Exenatide or Semaglutide better for manage weight?

For manage weight, Semaglutide has a higher relevance score (88 vs 46).

Can I take Exenatide and Semaglutide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.